Specifically, patients with non-neuroendocrine tumors displaying strong and diffuse p16Ink4A overexpression had a considerable better outcome compared to p16Ink4A-negative non-neuroendocrine carcinomas, while patients with tumors showing sporadic and focal staining patterns clustered together in an intermediate-risk group. This evidence concerns the gene CDKN2A and neuroendocrine neoplasm.